Dinaciclib (SCH727965)

Name: Dinaciclib (SCH727965)
Brand: Selleck Chemicals
SKU: S2768
Rating: 5 (89 reviews)

For research use only.

Catalog No.S2768 Synonyms: PS-095760

89 publications

Dinaciclib (SCH727965) Chemical Structure

CAS No. 779353-01-4

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.

Selleck's Dinaciclib (SCH727965) has been cited by 89 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 177(6):1463-1479

PubMed: 31080065 ( click the link to review the publication )

Cell, 2019, 176(4):869-881

PubMed: 30735636 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290

PubMed: 31466944 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Gut, 2021, 70(5):890-899

PubMed: 32816920 ( click the link to review the publication )

Sci Adv, 2021, 7(7)eabd2645

PubMed: 33579708 ( click the link to review the publication )

Sci Adv, 2021, 7(6)eabd6263

PubMed: 33547076 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Eur J Cancer, 2021, 145:92-108

PubMed: 33429148 ( click the link to review the publication )

Cancers (Basel), 2021, 13(10)2396

PubMed: 34063457 ( click the link to review the publication )

Cancers (Basel), 2021, 13(5)1135

PubMed: 33800911 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):54

PubMed: 33723248 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(5)2702

PubMed: 33800107 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Cell Death Dis, 2021, 12(2):179

PubMed: 33589591 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Mol Cancer, 2020, 19(1):139

PubMed: 32907612 ( click the link to review the publication )
Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):754

PubMed: 32934219 ( click the link to review the publication )

Am J Cancer Res, 2020, 1;10(4):1194-1206 eCollection 2020

PubMed: 32368395 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):148-163

PubMed: 32064158 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Sci Rep, 2020, 10(1):18489

PubMed: 33116269 ( click the link to review the publication )

Am J Transl Res, 2020, 15;12(3):1031-1043 eCollection 2020

PubMed: 32269732 ( click the link to review the publication )

Molecules, 2020, 25(20)E4606

PubMed: 33050377 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1661-1672

PubMed: 32236619 ( click the link to review the publication )

Neuroendocrinology, 2020, 10.1159/000509865

PubMed: 32615570 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Cell Res, 2019, 29(9):725-738

PubMed: 31273297 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5114

PubMed: 31704972 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2204

PubMed: 31101827 ( click the link to review the publication )

EMBO J, 2019, 38(19):e101704

PubMed: 31429971 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31439587 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2208-2219

PubMed: 30885981 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.222935

PubMed: 31289198 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(8):e8828

PubMed: 31464372 ( click the link to review the publication )

Cell Rep, 2019, 29(11):3394-3404

PubMed: 31825824 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561409 ( click the link to review the publication )
Cell Chem Biol, 2019, 26(1):121-130

PubMed: 30472117 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1520-1532

PubMed: 31243099 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Sci Rep, 2019, 9(1):3816

PubMed: 30846724 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2324

PubMed: 31207099 ( click the link to review the publication )

Odontology, 2019, 1007/s10266-019-00451-5

PubMed: 31529315 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

Blood Adv, 2019, 3(16):2448-2452

PubMed: 31416822 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Oncogene, 2018, 37(21):2850-2862

PubMed: 29511348 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):700

PubMed: 29899409 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(6):663-675

PubMed: 30178167 ( click the link to review the publication )

Mol Carcinog, 2018, 57(4):469-482

PubMed: 29240261 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):6608-6614

PubMed: 30405800 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 175(5):1244-1258

PubMed: 30454645 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9441-9454

PubMed: 28934491 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3738-3751

PubMed: 28062857 ( click the link to review the publication )

EMBO J, 2017, 36(2):202-212

PubMed: 27852626 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

Sci Rep, 2017, 7(1):14077

PubMed: 29074977 ( click the link to review the publication )

PLoS One, 2017, 12(5):e0177871

PubMed: 28520795 ( click the link to review the publication )
PLoS One, 2017, 12(2):e0172315

PubMed: 28207834 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83432-83445

PubMed: 29137354 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96506-96521

PubMed: 29228549 ( click the link to review the publication )

Oncotarget, 2017, 8(35):59476-59491

PubMed: 28938651 ( click the link to review the publication )

Cell Rep, 2016, 17(9):2367-2381

PubMed: 27880910 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.471

PubMed: 27991934 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

Sci Rep, 2016, 6:29090

PubMed: 27378523 ( click the link to review the publication )

Leukemia, 2015, 10.1038/leu.2015.99

PubMed: 25882699 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Oncotarget, 2015, 6(33):34629-48

PubMed: 26431489 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26219338 ( click the link to review the publication )

Assay Drug Dev Technol, 2015, 13(10):638-49

PubMed: 26192013 ( click the link to review the publication )

J Clin Invest, 2014, 124(8):3325-38

PubMed: 25036710 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(11):2360-5

PubMed: 24007471 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Targets

CDK2 ^[1] (Cell-free assay)	CDK5 ^[1] (Cell-free assay)	CDK1 ^[1] (Cell-free assay)	CDK9 ^[1] (Cell-free assay)
1 nM	1 nM	3 nM	4 nM

In vitro

Dinaciclib is also a potent DNA replication inhibitor that blocks thymidine (dThd) DNA incorporation in A2780 cells with IC50 of 4 nM. Dinaciclib strongly suppresses phosphorylation of Rb on Ser 807/811 at concentrations >6.25 nM, which is in agreement with the observation that 4 nM concentrations are required for 50% inhibition of dThd DNA incorporation in the same cell model. Significantly, complete suppression of Rb phosphorylation is correlated with the onset of apoptosis, as indicated by the appearance of the p85 PARP cleavage product in cells exposed to >6.25 nM Dinaciclib. Dinaciclib is active against a broad spectrum of human tumor cell lines. ^[1] Addition of Dinaciclib during hydroxyurea exposure also suppresses accumulation of γ-H2AX, in a dose-dependent manner. ^[2] Dinaciclib inhibits melanoma cell proliferation, and drives melanoma cells into massive apoptosis. ^[3] Dinaciclib induces the apoptosis of several osteosarcoma cell lines including those resistant to doxorubicin and dasatinib. Dinaciclib attenuates the phosphorylation of RNAP II at serine 2 and the phosphorylation of the CDK inhibitor p27^Kip1 at threonine 187. Reductions in phosphorylation activity occurrs at 12 - 40 nM Dinaciclib (4 to 16 hours post-Dinaciclib addition). Dinaciclib also reduces the phosphorylation of Rb at serine 807/811. Dinaciclib induces the apoptosis of mock- and p53-depleted U2OS cells to a similar extent. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CA46	MmriRZBweHSxc3nzJGF{e2G7	MWixNFAhdk1?	NYHuc\|M6OjRiaB?=	NV21Sm5bcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=>	NX\RZ5RwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPFk5QDdpPkK1Nlg6QDh5PD;hQi=>
Kasumi-1	Ml\DRZBweHSxc3nzJGF{e2G7	NXLp[\|FTOTByIH7N	NFXPepozPCCq	MYHpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ6OUi4O{c,OjV{OEm4PFc9N2F-
U937	NETnbYRHfW6ldHnvckBCe3OjeR?=	MXyyM\|UwOTBibl2=	NFvGbYc{KGh?	MmS2Zoxw[2u\|IHnu[JVkfGmxbjDv[kBZSlBvMYOgZY5lKGSxd37zeJJm[W1idHHy[4V1ew>?	MkfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NkK0OlUoRjJ2M{[yOFY2RC:jPh?=
8226	M3\XUmZ2dmO2aX;uJGF{e2G7	NVXlcoh1Oi93L{GwJI5O	NX3UOnl{PCCq	MWDicI9kc3NiaX7keYN1cW:wIH;mJHhDWC1zczDhcoQh\G:5boP0doVidSC2YYLn[ZR{	MnTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NkK0OlUoRjJ2M{[yOFY2RC:jPh?=
H929	NEToVIFHfW6ldHnvckBCe3OjeR?=	M2HVOVIwPS9zMDDuUS=>	NHLySJI1KGh?	Ml:wZoxw[2u\|IHnu[JVkfGmxbjDv[kBZSlBvMYOgZY5lKGSxd37zeJJm[W1idHHy[4V1ew>?	NVTwS4N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlI1PjVpPkK0N\|YzPDZ3PD;hQi=>
K562	M3ztc2Z2dmO2aX;uJGF{e2G7	MXGxMlUwOy96IH7N	MX62JIg>	MY\icI9kc3NiaX7keYN1cW:wIH;mJHhDWC1zczDhcoQh\G:5boP0doVidSC2YYLn[ZR{	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4MkS2OUc,OjR\|NkK0OlU9N2F-
BaF3/Bcr-abl	Mnv3SpVv[3Srb36gRZN{[Xl?	Mm[zNU42NzNxODDuUS=>	MmSzOkBp	M3frToJtd2OtczDpcoR2[3Srb36gc4YhYEKSLUHzJIFv\CCmb4fud5Rz\WGvIIThdodmfHN?	NVrLeY5kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlI1PjVpPkK0N\|YzPDZ3PD;hQi=>
U937	MmHYSpVv[3Srb36gRZN{[Xl?	NUO5XYRUOi9zMDDuUS=>	M{jSS\|MhcA>?	M4DadYJtd2OtczDpcoR2[3Srb36gc4YhYEKSLUHzJIFv\CCmb4fud5Rz\WGvIIThdodmfHN?	NInRc5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2NlQ3PSd-MkSzOlI1PjV:L3G+
1205Lu	MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHRNVAwOzBibl2=	M{OxRlczKGh?	M1XVe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGGwZDDzeZJ3cX[jbB?=	NEXST2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyO\|IzPSd-MkO1NlczOjV:L3G+
WM1366	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPtU\|EyOC9\|MDDuUS=>	MYe3NkBp	MVPpcohq[mm2czDj[YxtKGe{b4f0bEBidmRic4Xyeol3[Wx?	NF7pZ\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyO\|IzPSd-MkO1NlczOjV:L3G+
RD	NWn6UWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGjrRYNKSzVyPUiuNkBvVQ>?	NUWzRlRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVUzPDBpPkKyN\|E2OjRyPD;hQi=>
Rh41	M2P0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{HU[2lEPTB;MUCuOUBvVQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNUK0NEc,OjJ\|MUWyOFA9N2F-
Rh18	NHvYS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX7yVoo{UUN3ME2xNE42KG6P	NVixc2p4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVUzPDBpPkKyN\|E2OjRyPD;hQi=>
Rh30	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTlibl2=	NW\mdoF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVUzPDBpPkKyN\|E2OjRyPD;hQi=>
BT-12	M3:yS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUHJR\|UxRThwNTDuUS=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNUK0NEc,OjJ\|MUWyOFA9N2F-
CHLA-266	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1TTcWlEPTB;Nz6zJI5O	MkjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|MUWyOFAoRjJ{M{G1NlQxRC:jPh?=
TC-71	NYPPfYsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWfJR\|UxRTNwOTDuUS=>	NHi1[FY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOVI1OCd-MkKzNVUzPDB:L3G+
CHLA-9	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmO4TWM2OD16IH7N	M1LiNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{G1NlQxLz5{MkOxOVI1ODxxYU6=
CHLA-10	M2nPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoXJTWM2OD14LkOgcm0>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNUK0NEc,OjJ\|MUWyOFA9N2F-
CHLA-258	NY[3SZhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkW0TWM2OD17Lkmgcm0>	NWjqVVMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVUzPDBpPkKyN\|E2OjRyPD;hQi=>
GBM2	NX[4XG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NInsVHhKSzVyPU[uOUBvVQ>?	Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|MUWyOFAoRjJ{M{G1NlQxRC:jPh?=
NB-1643	M1XiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWjJR\|UxRTNwMzDuUS=>	M3yxSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{G1NlQxLz5{MkOxOVI1ODxxYU6=
NB-EBc1	NYTpXoZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MU\JR\|UxRTdibl2=	NIm2WJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOVI1OCd-MkKzNVUzPDB:L3G+
CHLA-90	M2Dy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml6yTWM2OD15LkWgcm0>	M{\CTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{G1NlQxLz5{MkOxOVI1ODxxYU6=
CHLA-136	NETZcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXXzXnRwUUN3ME25Mlghdk1?	NEDLVGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOVI1OCd-MkKzNVUzPDB:L3G+
NALM-6	NHnYVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4iwS2lEPTB;ND62JI5O	NHGwUnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOVI1OCd-MkKzNVUzPDB:L3G+
COG-LL-317	MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYTJR\|UxRTZwNTDuUS=>	NVXxbplKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVUzPDBpPkKyN\|E2OjRyPD;hQi=>
RS4;11	NXzEXI1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{S3PGlEPTB;NT6xJI5O	MlzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|MUWyOFAoRjJ{M{G1NlQxRC:jPh?=
MOLT-4	NYHLNpRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2nRPGlEPTB;OT6zJI5O	NFT1fVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOVI1OCd-MkKzNVUzPDB:L3G+
CCRF-CEM	NVHyZZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3jNVWlEPTB;NT62JI5O	NVvWbIhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVUzPDBpPkKyN\|E2OjRyPD;hQi=>
Kasumi-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1XXVmlEPTB;ND61JI5O	NVLaOmpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVUzPDBpPkKyN\|E2OjRyPD;hQi=>
Karpas-299	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnvhTWM2OD1\|Lkmgcm0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNUK0NEc,OjJ\|MUWyOFA9N2F-
Ramos-RA1	NF62PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWfKZlJ3UUN3ME23Mlkhdk1?	NHj4OG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOxOVI1OCd-MkKzNVUzPDB:L3G+
MIAPaCa-2	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVjTSXlCPzJiaB?=	MoqxS2k2OD1zMDDuUS=>	NFfVO489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe2PFc4QSd-MkG3Olg4Pzl:L3G+
Pa20C	NF3Wc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1nwblczKGh?	M3\td2dKPTB;MkCgcm0>	NF;RUHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe2PFc4QSd-MkG3Olg4Pzl:L3G+
ML-1	M1nxcmFxd3C2b4Ppd{BCe3OjeR?=	NVu3OpVyOS1zMECwJI5O	M1XrNVQhcA>?	MmjpbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd4OEe3O{c,OjF5Nki3O\|c9N2F-
Cytotoxicity assay	MlPYUWRCNU2ELUSzOi=>		NFHMNVk4OiCqcoO=	NX;TWWhHUUN3MDC9JFAvODB3IN88US=>	NV7rbmU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFA6OjVpPkKzOlAxQTJ3PD;hQi=>
Cytotoxicity assay	MXfOR2kuUDl{OR?=		M3jHXlczKGi{cx?=	M4nCUWlEPTBiPTCwMlAxPSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEmyOUc,OjN4MEC5NlU9N2F-
Cytotoxicity assay	MV3NSGEuVUJvMkOx		NInQ[Fc4OiCqcoO=	M2nOPGlEPTBiPTCwMlAxPSEQvF2=	NE[5U2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFkzPSd-MkO2NFA6OjV:L3G+
Cytotoxicity assay	MkLkV2suTVNvMR?=		NFH3d3A4OiCqcoO=	MVfJR\|UxKD1iMD6wNFUh\|ryP	NFLZZlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFkzPSd-MkO2NFA6OjV:L3G+
Cytotoxicity assay	NUjmOZF2STZ5Mx?=		NXSzNItZPzJiaILz	NELhZlNKSzVyIE2gNE4xODVizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEmyOUc,OjN4MEC5NlU9N2F-
Cytotoxicity assay	MknrV2suSlJvMx?=		MlS3O\|IhcHK\|	MnP0TWM2OCB;IECuNFA2KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEmyOUc,OjN4MEC5NlU9N2F-
Cytotoxicity assay	NHm2XWlOVk6JLVjPVy=>		MWq3NkBpenN?	MkToTWM2OCB;IECuNFA2PSEQvF2=	MnXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEC5NlUoRjJ\|NkCwPVI2RC:jPh?=
Cytotoxicity assay	M3;5cXNMNVWWLUG=		NXjGPXA4PzJiaILz	NGP5e3FKSzVyIE2gNE4xODZizszN	Mni1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEC5NlUoRjJ\|NkCwPVI2RC:jPh?=
Cytotoxicity assay	MYrVNlY3		NFjxWII4OiCqcoO=	MkLNTWM2OCB;IECuNFA3KM7:TR?=	NX;EfWk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFA6OjVpPkKzOlAxQTJ3PD;hQi=>
Cytotoxicity assay	MUDSVG1KOTh{Mk[=		NWj3UVlGPzJiaILz	NHXwVoZKSzVyIE2gNE4xODlizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEmyOUc,OjN4MEC5NlU9N2F-
Cytotoxicity assay	Mn;PV3c5PzJ?		MUi3NkBpenN?	NUnqTYtDUUN3MDC9JFAvODB7NTFOwG0>	NEnnZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFkzPSd-MkO2NFA6OjV:L3G+
Cytotoxicity assay	MWrUOFdF		NH;od\|k4OiCqcoO=	NUTXU\|l[UUN3MDC9JFAvODFizszN	NG\RWpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFkzPSd-MkO2NFA6OjV:L3G+
Apoptosis assay	NHeySHhCPjd\|		MXWyOEBpenN?	M2XrbGVEPTBiPTCwMlAyOSEQvF2=	NWfFSINXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFA6OjVpPkKzOlAxQTJ3PD;hQi=>
Cytotoxicity assay	NXzweplOVUOINx?=		NFHSfWI4OiCqcoO=	Mkj4TWM2OCB;IECuNFIh\|ryP	MmjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEC5NlUoRjJ\|NkCwPVI2RC:jPh?=
Function assay	MVfT[lk>			MXzJR\|UxKD1iMD6wO\|Ih\|ryP	M3n1O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{SxPFU{Lz5{Nke0NVg2OzxxYU6=
Function assay	NWXmfndJe2Z7			NGnLZ5RKSzVyIE2gNE4xODJizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh3MUWwOUc,OjZ6NUG1NFU9N2F-
Function assay	NFjNeZNU\jl?		MWSxJIhz	NXfGU2xKUUN3MDC9JFAvODBzIN88US=>	MlzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN\|YoRjJ5MUexNFM3RC:jPh?=
Function assay	M{O0fnNnQQ>?		M3nTV\|EhcHJ?	MkTBTWM2OCB;IECuNFAyKM7:TR?=	NX;TPXhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO\|ExOzZpPkK3NVcyODN4PD;hQi=>
Function assay	M{XCdHNnQQ>?		MnizNUBpeg>?	M1;mTmlEPTBiPTCwMlAxOSEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN\|Y9N2F-
Function assay	NGnRS3pU\jl?		MV2xJIhz	M1OwN2lEPTBiPTCwMlAxOSEQvF2=	MmDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN\|YoRjJ5MUexNFM3RC:jPh?=
Function assay	NVXIbZBtW2Z7		M13DdVEhcHJ?	MX7JR\|UxKD1iMD6wNFMh\|ryP	M3PFdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
Function assay	M4PoTnNnQQ>?		NFTreYIyKGi{	M2DKcWlEPTBiPTCwMlAxOyEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN\|Y9N2F-
Function assay	NGmxWlVU\jl?		Mor2NUBpeg>?	Mor3TWM2OCB;IECuNFA1KM7:TR?=	NVL0eJJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO\|ExOzZpPkK3NVcyODN4PD;hQi=>
Function assay	M3;qSXNnQQ>?		MY[xJIhz	NYXablU6UUN3MDC9JFAvODB2IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN\|Y9N2F-
Function assay	M1fZSnNnQQ>?	NFPM[IwyOCC3TR?=		NF[1eYRKSzVyIE2gNE4xODRizszN	NWP6UmFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNlk3PThpPkK5N\|I6PjV6PD;hQi=>
Function assay	NXO2WGo4W2Z7		NHjPe2YyKGi{	NIPi[lhKSzVyIE2gNE4xODFizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{OzPEc,Ojl6NUOzN\|g9N2F-
Function assay	MmG1V4Y6		NEHDd4UyKGi{	M4\ieGlEPTBiPTCwMlAxOSEQvF2=	NIXHd\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M{QCd-Mkm4OVM{Ozh:L3G+
Function assay	MknyV4Y6		M3rTVlEhcHJ?	MY\JR\|UxKD1iMD6wNFMh\|ryP	M{LzZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN\|M5Lz5{OUi1N\|M{QDxxYU6=
Function assay	NFjqXlJU\jl?		M2rmOlEhcHJ?	NV3XbpgyUUN3MDC9JFAvODB2IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{OzPEc,Ojl6NUOzN\|g9N2F-
Antiproliferative assay	MWjNU2xOOTN?		M4jXWlczKGi{cx?=	NUj3NYxlT0l3MDC9JFAvODB\|MzFOwG0>	MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Antiproliferative assay	MlfzUWVEOQ>?		MnXRO\|IhcHK\|	MVTHTVUxKD1iMD6wNFM3KM7:TR?=	M3fUbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkWzN\|Q3Lz5\|MEK1N\|M1PjxxYU6=
Antiproliferative assay	Ml;BUW9NVTF2		NWfqOYZ6PzJiaILz	MYLHTVUxKD1iMD6wNFQ2KM7:TR?=	NIT4PGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK1N\|M1Pid-M{CyOVM{PDZ:L3G+
Antiproliferative assay	MlHXR29NVzJyNR?=		NH24NXU4OiCqcoO=	MoTNS2k2OCB;IECuNFA3QCEQvF2=	MojiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Antiproliferative assay	NIPxZYlJVDZy		NEn6ZWw4OiCqcoO=	NWnoUIMxT0l3MDC9JFAvODB6IN88US=>	MnHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Antiproliferative assay	NFjxZolT[W2xcx?=		NGrvdIM4OiCqcoO=	Mme3S2k2OCB;IECuNFA5PiEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ3M{O0Okc,OzB{NUOzOFY9N2F-
Antiproliferative assay	NE\JcIRIUVOWVEG=		M1jUT\|czKGi{cx?=	M1vKUGdKPTBiPTCwMlAxQDhizszN	NFToOXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK1N\|M1Pid-M{CyOVM{PDZ:L3G+
Antiproliferative assay	NH;S[pRWQTN5		M17ZVlczKGi{cx?=	MVTHTVUxKD1iMD6wNUDPxE1?	MnXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Antiproliferative assay	M2DwZWE1OzF?		Moj6O\|IhcHK\|	M1;VT2dKPTBiPTCwMlAyOSEQvF2=	NEfsRnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK1N\|M1Pid-M{CyOVM{PDZ:L3G+
Antiproliferative assay	Mn7PV2tOOQ>?		NFj5V4U4OiCqcoO=	NIPpNY5IUTVyIE2gNE4xOTFizszN	Mkn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Antiproliferative assay	Mn3lUWVEOg>?		MX:3NkBpenN?	M4rWd2dKPTBiPTCwMlAyOSEQvF2=	NYfzcoVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOVM{PDZpPkOwNlU{OzR4PD;hQi=>
Antiproliferative assay	MWnBN\|c2		MlLZO\|IhcHK\|	NHXIOVZIUTVyIE2gNE4xOTFizszN	MknZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Antiproliferative assay	NVrldXd5V0OLLVHNUFM>		NHvxNWU4OiCqcoO=	M1nvUWdKPTBiPTCwMlAyOyEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ3M{O0Okc,OzB{NUOzOFY9N2F-
Antiproliferative assay	MmTzRmUpOilvTUG3		M3jrOVczKGi{cx?=	NUH6WWl6T0l3MDC9JFAvODJzIN88US=>	Mor6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Antiproliferative assay	M3XCO2NJVw>?		NYXE[plYPzJiaILz	NXLLXWpGT0l3MDC9JFAvOTZizszN	NIG3SXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK1N\|M1Pid-M{CyOVM{PDZ:L3G+
Function assay	NUTtfW9MVkOLLVi5Nlk>	NUL3fGRNOC5yMEWgeW0>	NY\JR4lTOjRiaILz	M1TJPWlvcGmkaYTpc44hd2ZiQ1TLNk1u\WSrYYTl[EBT[iCyaH;zdIhwenmuYYTpc44h[XRiU3XyJFgxPy96MUGgbY4hcHWvYX6gUmNKNUh7MkmgZ4VtdHNiYYSgNE4xODVidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5oKGGwYXz5d4l{	MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEC5NlUoRjJ\|NkCwPVI2RC:jPh?=
Function assay	NWn1bW0zSTZ5Mx?=	MWmwMlA2KHWP	MXWyOEBpenN?	NEjBOI5KdmirYnn0bY9vKG:oIFPET\|IudWWmaXH0[YQhWmJicHjvd5Bpd3K7bHH0bY9vKGG2IGPldkA5ODdxOEGxJIlvKGi3bXHuJGE3PzNiY3XscJMh[XRiMD6wOUB2VSCjZoTldkAzPCCqcoOgZpkhcW2vdX7vZoxwfHSrbnegZY5idHm\|aYO=	NYjPN41ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFA6OjVpPkKzOlAxQTJ3PD;hQi=>
Apoptosis assay	NUn5bWFUVUWFMR?=	MVmwMlAyKHWP	NX;CUY9vOjRiaILz	M1rhUGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTVXDNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCPQ1ytNUBt\X[nbDDheEAxNjBzIIXNJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\yCjbnHsfZNqew>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ3M{O0Okc,OzB{NUOzOFY9N2F-
Apoptosis assay	NWTpU5ZHUEx4MB?=	MUOwMlAyKHWP	NXOxNGYyOjRiaILz	NGjsW\|ZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjMOlAh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iTVPMMVEhdGW4ZXygZZQhOC5yMTD1UUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmdiYX7hcJl{cXN?	MnT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Apoptosis assay	NXzKR3FDVVZ2LUGx	MUewMlAyKHWP	MXmyOEBpenN?	MVXJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClLV3ZR{Bt\X[nbDDheEAxNjBzIIXNJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\yCjbnHsfZNqew>?	MoHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUOzOFYoRjNyMkWzN\|Q3RC:jPh?=
Apoptosis assay	NYDMfXFDVUWFMR?=	MVuwMlAyKHWP	NHTJcY4zPCCqcoO=	MkXaTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPRVOxJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGNvTWnDJIxmfmWuIHH0JFAvODFidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5oKGGwYXz5d4l{	NFnSfXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK1N\|M1Pid-M{CyOVM{PDZ:L3G+
Apoptosis assay	MkLqUXY1NTFz	NYL2ZZh5OC5yMTD1US=>	NHLZUGQzPCCqcoO=	NGP4eIRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3WOE0yOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDNR2wuOSCuZY\lcEBifCByLkCxJJVOKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrcx?=	NHq5fGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK1N\|M1Pid-M{CyOVM{PDZ:L3G+
Apoptosis assay	NGjnVJVJVDZy	NUnkTlliOC5yMTD1US=>	MUCyOEBpenN?	NGLKOJFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjMOlAh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iYz3NXWMhdGW4ZXygZZQhOC5yMTD1UUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmdiYX7hcJl{cXN?	NF;jcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK1N\|M1Pid-M{CyOVM{PDZ:L3G+
Cytotoxicity assay	NXXafmdPXTKRUx?=		Mn7SPVYhcHK\|	NHTUXW9KSzVyIE2gNE4xODZizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDRyLze+R4hGVUKOPD;hQi=>
Function assay	NGPMWIZWOk:V		NF\UeGoyKGi{	MXvJR\|UxKD1iMD6wNFch\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDRyLze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / c-Myc; PubMed: 25289887 PLoS One Immunoblot analysis of A2780 cells during the 5 hr time-course treatment of Dinaciclib (100 nM). Mcl-1 / Bcl-2 / Bcl-xl / Bax / Bak / PUMA / Noxa; PubMed: 28714472 Nat Commun H196 cells treated with doxorubicin for the indicated times were assessed by immunoblot analysis. RNAP II (P-Ser2/P-Ser5); PubMed: 25289887 PLoS One Immunoblot analysis of A2780 cells during the 5 hr time-course treatment of Dinaciclib (100 nM). Survivin; PubMed: 28207834 PLoS One Western blot analysis was performed in cells treated with dinaciclib (25 nM) or vehicle for the indicated time. The levels of Mcl-1, Bcl-xL and survivin were evaluated in BHP7-13, WRO82-1 and 8505C cells.	25289887 28714472 28207834
Growth inhibition assay	Cell viability; PubMed: 28361959 Sci Rep (a-c) The number of cells after dinaciclib treatment. Cell number in 49 fields (7 × 7) was calculated and shown in the graph (n = 4). (a) Total cell number. p < 0.01 vs control. (b) Number of OCT4 positive cells. p < 0.01 vs control. (c) Number of OCT4 negative cells. n.s., not significant. (d) The percentage of OCT4 positive cells. *p < 0.01 vs control. p < 0.05 vs 6 nM. Cell viability; PubMed: 27378523 Sci Rep (a) Six typical NB cell lines were treated with increasing concentrations of dinaciclib for 48 hrs. Cell viability was then measured by the Cell Counting Kit-8 (CCK-8) assay. P-values < 0.01 () or P < 0.001 (*) (Student's t-test, two-tailed) were indicated. (b) The IC50 values of dinaciclib on each cell line listed were calculated based on the data in (a).	28361959 27378523
Immunofluorescence	cyclin B1 / α-tubulin / Aurora A; PubMed: 28207834 PLoS One (B) Cells were treated with dinaciclib (25 nM) or placebo for 24 h and stained with fluorescent antibodies against DAPI (blue), cyclin B1 (red) and α-tubulin (green). Cyclin B1 level was significantly reduced after treatment of dinaciclib in prophase cells of BHP7-13, WRO82-1 and 8505C. (C) Cells were treated with dinaciclib (25 nM) or placebo for 24 h and stained with fluorescent antibodies against DAPI (blue), Aurora A (red) and α-tubulin (green). Aurora A level was significantly reduced after treatment of dinaciclib in BHP7-13, WRO82-1 and 8505C cells in prophase. Scale bar, 10 μm. OCT4; PubMed: 28361959 Sci Rep Representative images of OCT4 positive cells (red). Nuclei were stained with Hoechst (blue). Scale bars = 200 μm.	28207834 28361959

In vivo

Dinaciclib i.p. administration at 8, 16, 32, and 48 mg/kg daily for 10 days results in tumor inhibition by 70%, 70%, 89%, and 96%, respectively. Dinaciclib MED (minimum effective dose) appears to be <8 mg/kg. Dinaciclib is well tolerated, and the maximum body weight loss in the highest dosage group is 5%. Dinaciclib has dose-dependent antitumor activity in vivo, and that nearly complete inhibition of tumor growth occurs at a dose level below the MTD (maximum tolerated dose). Dinaciclib has a short plasma half-life in mouse. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Cyclin/CDK kinase assay: Recombinant cyclin/CDK holoenzymes are purified from Sf9 cells engineered to produce baculoviruses that express a specific cyclin or CDK. Cyclin/CDK complexes are typically diluted to a final concentration of 50 μg/mL in a kinase reaction buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM MgCl₂, 1 mM DTT, and 0.1 mM sodium orthovanadate. For each kinase reaction, 1 μg of enzyme and 20 μL of a 2-μM substrate solution (a biotinylated peptide derived from histone H1) are mixed and combined with 10 μL of diluted Dinaciclib. The reaction is started by the addition of 50 μL of 2 μM ATP and 0.1 μCi of ³³P-ATP. Kinase reactions are incubated for 1 hour at room temperature and are stopped by the addition of 0.1% Triton X-100, 1 mM ATP, 5 mM EDTA, and 5 mg/mL streptavidin-coated SPA beads. SPA beads are captured using a 96-well GF/B filter plate and a Filtermate universal harvester. Beads are washed twice with 2 M NaCl and twice with 2 M NaCl containing 1% phosphoric acid. The signal is then assayed using a TopCount 96-well liquid scintillation counter.
Cell Research:^[1]	- Collapse Cell lines: A2780 cells Concentrations: 0 μM -5 μM Incubation Time: 24 hours Method: A2780 cells are maintained in DMEM plus 10% fetal bovine serum and passaged twice weekly by detaching the monolayer with trypsin-EDTA. One hundred microliters of A2780 cells (5 × 10³ cells) are added per well to a 96-well Cytostar-T plate and incubated for 16 hours to 24 hours at 37 °C. Dinaciclib is serially diluted in complete media plus 2% ¹⁴C-labeled dThd. Media are removed from the Cytostar T plate; 200 μL of various Dinaciclib dilutions are added in quadruplicate; and the cells are incubated for 24 hours at 37 °C. Accumulated incorporation of radiolabel is assayed using scintillation proximity and measured on a TopCoun^TM. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Nude mice bearing A2780 tumors Dosages: 8 mg/kg, 16 mg/kg, 32 mg/kg, and 48 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Fu W, et al. Mol Cancer Ther. 2011, 10(6), 1018-1027.

- Collapse

Solubility (25°C)

In vitro	DMSO	26 mg/mL warmed (65.57 mM)
	Ethanol	8 mg/mL warmed (20.17 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dinaciclib (SCH727965) SDF

Molecular Weight	396.49
Formula	C₂₁H₂₈N₆O₂
CAS No.	779353-01-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	PS-095760
Smiles	CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03484520	Active not recruiting	Drug: Venetoclax\|Drug: Dinaciclib	Cancer - Acute Myeloid Leukemia	AbbVie\|Merck Sharp & Dohme Corp.	July 23 2018	Phase 1
NCT01434316	Recruiting	Drug: Dinaciclib\|Drug: Veliparib	Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	November 1 2011	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to know how to reconstitute the inhibitor for in vivo studies?
Answer:
S2768 (SCH727965) in 15% Captisol at 8 mg/ml is a suspension for oral administration. And it can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution for injection.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Selective CDK Inhibitor

SNS-032 (BMS-387032) : CDK2-selective, IC50=48 nM.
Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Palbociclib (PD0332991) Isethionate : Phase III for Metastatic Breast Cancer.
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Flavopiridol (L86-8275) HCl

Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (CYC202)

Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Dinaciclib (SCH727965)